Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

BMS to buy hep C firm Inhibitex for $2.5 billion

January 9, 2012 Research and Development, Sales and Marketing BMS, Inhibitex, hep C

Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …
News

Celgene appoints Dr David Gillen as its UK and Ireland medical director

January 9, 2012 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene

Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …
Appointment
Merkel and Sarkozy

2011 Year In Review

January 6, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Europe, emerging markets, year in review

A round up of some of the key themes in pharma’s yearEUROPE IN CRISIS While the Eurozone has averted meltdown …
Feature

New requirements for the technical validations of Marketing Authorisation Applications

January 6, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The current EU- eCTD v3.1 validation criteria came into force on 1st September 2011 for the technical validation for all …
News
Press release

GSK faces fine over Argentina clinical trial

January 6, 2012 Research and Development, Sales and Marketing Argentina, GSK, Vaccine, deaths, emerging markets

A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …
News

Biogen inks $299m deal for rare genetic disorder drug

January 5, 2012 Research and Development, Sales and Marketing Biogen, Isis Pharma

Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …
News

AstraZeneca to take Alzheimer’s drug into phase II

January 5, 2012 Research and Development Alzheimer's, AstraZeneca, Targacept

AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …
News

Orphan status for haemophilia gene therapy

January 4, 2012 Research and Development AMT, gene therapy, haemophilia

Amsterdam Molecular Therapeutics has been granted an orphan drug designation for its gene therapy for haemophilia B.The FDA’s orphan designation …
News

Missing trial data ‘threatens integrity of medicine’

January 4, 2012 Research and Development, Sales and Marketing BMJ, clincial trial data, disclosure

Missing clinical trial data can harm patients and lead to needless costs for health systems, according to new research. A …
News

FDA accepts Pfizer’s arthritis pill for review

December 22, 2011 Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib

The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …
News

AstraZeneca, Novo and Enlight sign collaborative research deal

December 20, 2011 Research and Development, Sales and Marketing AstraZeneca, Enlight, Novo Nordisk

AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …
News

AstraZeneca posts drug failures, takes $382m hit

December 20, 2011 Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer

AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …
News
Gilenya picture

Key product launches of 2011

December 19, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Feature

Vertex chief to step down; names Jeffrey Leiden as new leader

December 19, 2011 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Abbott, Vertex

Vertex has named a new chief executive to succeed Matthew Emmens, who will retire early next year. He will be …
Appointment

Amgen’s chief executive and chairman Kevin Sharer to retire

December 16, 2011 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Amgen

Kevin Sharer, Amgen’s chairman and chief executive, has announced his retirement next year, leading the way for Robert Bradway to …
Appointment
The Gateway to Local Adoption Series

Latest content

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026

Scotland starts newborn screening for SMA

March 26, 2026

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026